Patents Assigned to Vacsyn S.A.
  • Publication number: 20020010132
    Abstract: The use of non-toxic muramyl peptides, particularly Murabutide and Murametide, to prepare drugs for inhibiting HIV replication in humans is disclosed. Said muramyl peptides are capable of up to 100% inhibition of retroviral replication in primary host monocyte cultures.
    Type: Application
    Filed: June 13, 1997
    Publication date: January 24, 2002
    Applicant: VACSYN S.A.
    Inventor: Georges BAHR
  • Patent number: 6267968
    Abstract: Pharmaceutical compositions containing Muramyl dipeptide derivatives and conjugates or Muramyl dipeptide derivatives and conjugates combined with nucleoside derivatives which induce hematopoietic stem cell stimulation and mobilization into the circulating blood system. Methods to induce hematopoietic stem stimulation and mobilization, as well as methods to decrease myelotoxic effects using these pharmaceutical compositions.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: July 31, 2001
    Assignee: Vacsyn S.A.
    Inventors: Georges Bahr, Pierre Lefrancier, Louis Chedid
  • Patent number: 6063380
    Abstract: Vaccines, composed of antigens absorbed on alum or formulated in an alum-containing composition, have enhanced immunogenicity over existing vaccines. The vaccines of the invention are characterized by their combination with 2-120 .mu.g per kg or 0.1 to 6 mg by dose, preferentially 6-60 .mu.g per kg or 0.3 to 3 mg per dose, of a hydrosoluble muramyl peptide.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: May 16, 2000
    Assignee: Vacsyn S.A.
    Inventors: Louis Chedid, Francoise Audibert
  • Patent number: 5932208
    Abstract: A therapeutical composition for use in humans, comprising a combination of at least one natural or recombinant and preferably human cytokine with at least one muramyl peptide selected from those which, when administered in vivo together with an interferon, also induce an increased in vivo production of an interleukin-1 receptor antagonist IL-1 RA, but preferably do not induce any increase in TNF, IL-8 and IL-1 cytokines. Said composition is useful for antiviral and antitumoral therapies and/or for promoting restoration of the haematopoietic system, particularly in individuals with a weakened immune system.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: August 3, 1999
    Assignee: Vacsyn S.A.
    Inventors: Louis Chedid, Georges Bahr, Pierre Lefrancier